Camurus Interim Report January-September 2019
”In the third quarter, we saw a marked increase in our revenues and the number of patients treated with Buvidal® for opioid dependence” Summary third quarter 2019 · Net revenues in the quarter were MSEK 40.2 (19.6) and MSEK 70.6 (41.5) in January-September · Product sales were MSEK 19.5 (0.3) for the quarter and MSEK 41.8 (6.2) in January-September · Product sales increased by 75 percent compared to the previous quarter · Buvidal® was listed for price and reimbursement in Norway, Australia, Scotland, Wales and Northern Ireland · The District Court for the District of